LXRX
Price:
$1.61
Market Cap:
$582.00M
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.[Read more]
Industry
Biotechnology
IPO Date
2000-04-07
Stock Exchange
NASDAQ
Ticker
LXRX
According to Lexicon Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 73.27%. This represents a change of -433.46% compared to the average of -21.97% of the last 4 quarters.
The mean historical ROE of Lexicon Pharmaceuticals, Inc. over the last ten years is -59.87%. The current 73.27% ROE has changed -222.38% with respect to the historical average. Over the past ten years (40 quarters), LXRX's ROE was at its highest in in the June 2018 quarter at 684.40%. The ROE was at its lowest in in the March 2018 quarter at -160.63%.
Average
-59.87%
Median
-22.51%
Minimum
-247.69%
Maximum
8.19%
Discovering the peaks and valleys of Lexicon Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 5.39%
Maximum Annual ROE = 8.19%
Minimum Annual Increase = -3032.33%
Minimum Annual ROE = -247.69%
Year | ROE | Change |
---|---|---|
2023 | -190.23% | -3032.33% |
2022 | 6.49% | 9.34% |
2021 | 5.93% | -113.22% |
2020 | -44.88% | 362.67% |
2019 | -9.70% | -218.42% |
2018 | 8.19% | -103.31% |
2017 | -247.69% | 175.66% |
2016 | -89.85% | 5.39% |
2015 | -1.64% | -95.36% |
2014 | -35.31% | -440.48% |
The current ROE of Lexicon Pharmaceuticals, Inc. (LXRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-59.27%
5-year avg
-46.48%
10-year avg
-59.87%
Lexicon Pharmaceuticals, Inc.’s ROE is less than BioLineRx Ltd. (0%), greater than Ardelyx, Inc. (-225.62%), greater than Seres Therapeutics, Inc. (-39.73%), less than ImmunityBio, Inc. (313.56%), less than eFFECTOR Therapeutics, Inc. (100.06%), less than X4 Pharmaceuticals, Inc. (2.18%), less than Elevation Oncology, Inc. (32.93%), greater than Mereo BioPharma Group plc (-57.97%), greater than Hepion Pharmaceuticals, Inc. (-63.39%), greater than Galera Therapeutics, Inc. (-328.66%), less than Terns Pharmaceuticals, Inc. (21.95%), greater than Day One Biopharmaceuticals, Inc. (-39.58%), greater than HOOKIPA Pharma Inc. (-122.70%), greater than Enveric Biosciences, Inc. (-51.77%), greater than CohBar, Inc. (-234.16%), greater than Ocean Biomedical, Inc. (-55.32%), less than AVROBIO, Inc. (567.07%), less than null (29.68%),
Company | ROE | Market cap |
---|---|---|
0% | $55.61M | |
-225.62% | $1.32B | |
-39.73% | $145.36M | |
313.56% | $2.35B | |
100.06% | $188.18K | |
2.18% | $109.78M | |
32.93% | $36.94M | |
-57.97% | $664.26M | |
-63.39% | $4.20M | |
-328.66% | $4.08M | |
21.95% | $549.60M | |
-39.58% | $1.25B | |
-122.70% | $159.50M | |
-51.77% | $4.53M | |
-234.16% | $1.25M | |
-55.32% | $33.96M | |
567.07% | $5.24M | |
29.68% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lexicon Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lexicon Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Lexicon Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Lexicon Pharmaceuticals, Inc. (LXRX)?
What is the highest ROE for Lexicon Pharmaceuticals, Inc. (LXRX)?
What is the 3-year average ROE for Lexicon Pharmaceuticals, Inc. (LXRX)?
What is the 5-year average ROE for Lexicon Pharmaceuticals, Inc. (LXRX)?
How does the current ROE for Lexicon Pharmaceuticals, Inc. (LXRX) compare to its historical average?